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Abstract
Introduction: The global target for 2020 is that ≥90% of people living with HIV (PLHIV) receiving antiretroviral therapy (ART)
will achieve viral load suppression (VLS). We examined VLS and its determinants among adults receiving ART for at least four
months.
Methods: We analysed data from the population-based HIV impact assessment (PHIA) surveys in Eswatini, Lesotho, Malawi,
Zambia and Zimbabwe (2015 to 2017). PHIA surveys are nationally representative, cross-sectional household surveys. Data
collection included structured interviews, home-based HIV testing and laboratory testing. Blood samples from PLHIV were
analysed for HIV RNA, CD4 counts and recent exposure to antiretroviral drugs (ARVs). We calculated representative esti-
mates for the prevalence of VLS (viral load <1000 copies/mL), nonsuppressed viral load (NVL; viral load ≥1000 copies/mL),
virologic failure (VF; ARVs present and viral load ≥1000 copies/mL), interrupted ART (ARVs absent and viral load
≥1000 copies/mL) and rates of switching to second-line ART (protease inhibitors present) among PLHIV aged 15 to 59 years
who participated in the PHIA surveys in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe, initiated ART at least four months
before the survey and were receiving ART at the time of the survey (according to self-report or ARV testing). We calculated
odds ratios and incidence rate ratios for factors associated with NVL, VF, interrupted ART, and switching to second-line ART.
Results: We included 9200 adults receiving ART of whom 88.8% had VLS and 11.2% had NVL including 8.2% who experi-
enced VF and 3.0% who interrupted ART. Younger age, male sex, less education, suboptimal adherence, receiving nevirapine,
HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of
NVL. Among people with NVL, marriage, female sex, shorter ART duration, higher CD4 count and alcohol use were associated
with lower odds for VF and higher odds for interrupted ART. Many people with VF (44.8%) had CD4 counts <200 cells/µL,
but few (0.31% per year) switched to second-line ART.
Conclusions: Countries are approaching global VLS targets for adults. Treatment support, in particular for younger adults, and
people with higher CD4 counts, and switching of people to protease inhibitor- or integrase inhibitor-based regimens may fur-
ther reduce NVL prevalence.
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1 | INTRODUCTION
The Joint United Nations Programme on HIV/AIDS (UNAIDS)
has set a target for 90% of people on ART to have viral load
suppression (VLS) by 2020 [1]. Maintaining VLS keeps HIV-
positive patients healthy and reduces the risk of HIV transmis-
sion [2-5]. Consistent retention and adherence to an effective
ART regimen are essential for maintaining VLS, but inadequate
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retention and adherence and use of ineffective ART regimens
are common, leading to reduced individual and public health
benefits of ART [6-8].
The World Health Organization (WHO) recommends rou-
tine viral load (VL) monitoring of patients receiving ART [9].
Recently, VL monitoring has been scaled up in resource-lim-
ited settings; however, in most sub-Saharan African coun-
tries, access remains limited. The proportion of patients who
had received at least one VL test by mid-2016 was 19% in
Malawi, 11% in Côte d’Ivoire, 49% in Kenya, 43% in Namib-
ia, 9% in Tanzania and 22% in Uganda [10]. For settings
with limited VL testing capacity, WHO recommends targeted
VL testing of patients with suspected treatment failure [9].
In settings without access to VL testing, healthcare workers
rely on immunological or clinical criteria to detect ART fail-
ure [6]. The diagnostic accuracy of these criteria for identi-
fying patients with virologic failure (VF) is poor, and
patients may not receive adherence support, may remain on
ineffective ART regimens or may be switched to second-line
ART unnecessarily [6]. Even where VL testing has been
implemented, patients may not benefit from clinical manage-
ment if results are not used for clinical decision-making
[6,11].
We analysed nationally representative data from the popu-
lation-based HIV impact assessment (PHIA) surveys in Eswa-
tini (formerly called Swaziland), Lesotho, Malawi, Zambia and
Zimbabwe to examine VLS and its determinants (interrupting
ART, VF and switching to second-line ART) among adults
receiving ART for at least four months.
2 | METHODS
2.1 | Survey design
The PHIA surveys are nationally representative, cross-sec-
tional household surveys. PHIA surveys use a two-stage clus-
ter-based sampling design. The surveys measure HIV
incidence, HIV prevalence and VLS prevalence among PLHIV
and progress towards each of the UNAIDS 90-90-90 targets.
The survey was conducted between 2015 and 2017 in the
five countries included in our analysis.
Data collection included structured household and individual
interviews, home-based HIV testing using each country’s
national rapid testing algorithm with immediate return of
results and further laboratory testing. HIV-positive blood
specimens were tested for plasma VL. If an insufficient volume
of plasma was collected HIV VL testing was performed on
dried blood spots (DBS). Positive specimens were also tested
for CD4 cell counts and the presence of selected antiretrovi-
ral drugs (ARVs). In each country, samples were tested for the
first-line ARVs efavirenz (EFV) and nevirapine (NVP) and the
second-line ARV lopinavir (LPV). Malawi and Zambia also
tested samples for the second-line ARV atazanavir (ATV). A
qualitative high-performance liquid chromatography/tandem
mass spectrometry assay was performed to detect antiretrovi-
ral drug (ARV) in DBS. A concentration of 0.02 lg/mL was
used as the cut-off. More details of laboratory and survey
methods are given in the appendix (Text S1) and in survey
reports [12-16] which are available online at https://phia.icap.c
olumbia.edu/resource_categories/final-reports/.
2.2 | Eligibility
We included HIV-positive adults aged 15 to 59 years who
participated in the five PHIA surveys, who consented to bio-
marker testing, who provided complete data on HIV aware-
ness and treatment status and who were classified as
receiving ART at the time of the survey either by reporting
current ART use or by having detectable blood levels of
selected ARVs. We excluded people who reported receiving
ART for less than four months to account for people with high
baseline VL who may not have had VLS at the time of data
collection.
2.3 | Measures
As per WHO definitions, we defined VLS as
VL < 1000 copies/mL and NVL as VL ≥ 1000 copies/mL [9].
People with NVL were classified as either experiencing VF if
any single ARV was detected in blood samples or as having
interrupted ART if no ARVs were detected. We classified regi-
mens as EFV-based if EFV was detected, as NVP-based if
NVP was detected, and as protease inhibitor (PI)-based if
either LPV or ATV was detected. We classified non-nucleoside
reverse-transcriptase inhibitors (NNRTI)-based regimens as
first-line ART and PI-based regimens as second-line ART [9].
CD4 cell count was categorized as <100, 100 to 199, 200 to
349, 350 to 499 and ≥500 cells/µL. VL was categorized as
<40, 40-999 and ≥1000 copies/mL. DBS VL samples could
not be categorized and were excluded from this analysis.
We calculated ART duration as the date of the survey inter-
view minus the self-reported ART start date. We categorized
ART duration as <1, 1 to 2, 2 to 5, 6 to 10 and >10 years.
We defined adherence to ART, based on self-reported data,
as optimal if a participant reported missing less than two
doses in the last 30 days or suboptimal if the participant
missed two or more doses in the last 30 days.
We used an asset-based wealth index and categorized the
wealth index scores into quintiles [17]. Households that
received cash transfer, assistance for school fees, material sup-
port for education or income generation support in cash or
other forms in the last 12 months were considered to have
received economic support. Work for which individuals received
a salary, cash or in-kind payment in the last 12 months was clas-
sified as paid work. Alcohol use was assessed with the AUDIT-C
three-item questionnaire. We used the cut-off AUDIT-C score
of ≥4 in men and ≥3 in women to classify people screening posi-
tive for hazardous drinking [18,19].
2.4 | Statistical analysis
We estimated the prevalence of VLS and NVL among people
receiving ART for at least four months and the prevalence of
VF and interrupted ART among those with NVL. In a sensitiv-
ity analysis, we examined how the exclusion of people who
received ART for less than four months affected NVL preva-
lence. We used bivariate and multivariable logistic regression
to calculate odds ratios (OR) for factors associated with NVL,
interrupted ART and VF. Logistic regression models accounted
for stratification and clustering in the sample design. We esti-
mated variance using the Taylor series linearization method.
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We used purposeful selection of covariates to build our
final regression models [20]. We considered characteristics of
ART and sociodemographic and behavioural characteristics in
bivariate analysis. Variables associated with the outcome at a
significance level of <0.20 in bivariate analysis [21,22] and
variables that had been reported as important determinants
of VLS or interruption of ART (i.e. wealth quintile, education
and ART duration) [23-29] were considered in multivariable
analysis. Variables not significant at the level <0.05 in multi-
variable analysis were successively eliminated from multivari-
able models starting with the least significant variable. After
eliminating a variable from the model, we compared the esti-
mates of all coefficients that remained in the smaller model to
their respective estimates from the larger model and added
the eliminated variable back into the model if an estimate
changed by more than 20%. We checked for interactions
between independent variables that remained in the final
model. We imputed missing data for all variables that were
considered in multivariable analysis using multiple imputation
with chained equations, ran multivariable analysis on 25
imputed datasets and pooled results using Rubin’s rules [30-
33]. Imputation models included all variables that were consid-
ered in multivariable analysis, NVL, VF, interruption of ART,
CD4 cell count, region and survey weights.
We calculated rates of switching to second-line ART as the
number of participants who switched divided by the person-
years on first-line ART. We had no data on the timing of
switching to second-line ART but assumed that participants
switched after 1.85 years, the median time from initiation of
first-line ART to switching to second-line ART in programs in
resource-limited settings without access to routine VL moni-
toring [34]. We calculated incidence rate ratios (IRR) compar-
ing switching rates by country, age, sex, CD4 count and urban
or rural residence using multivariable Poisson regression. In a
sensitivity analysis, we assumed that participants switched at
the earliest and latest possible times (i.e. six months after initi-
ating first-line ART and on the day of the survey). We
excluded participants with unknown ART start date and
unknown ART regimen from analysis of switching rates and
factors associated with switching. To ensure national popula-
tion-level representativeness of the survey, all analyses were
weighted for selection probability, non-response and non-cov-
erage using survey weights. We report weighted percentages
and unweighted numbers of participants in all analyses if not
stated otherwise. Statistical analysis was done using Stata
(Version 15, Stata Corporation, College Station, TX, USA).
2.5 | Ethical considerations
Local ethics committees and Institutional Review Boards
approved the PHIA surveys. All participants provided written
informed consent. Anonymized data were used for statistical
analyses. More details on research ethics are given in the
appendix (Text S2).
3 | RESULTS
3.1 | Inclusion and characteristics of participants
Out of the 13 852 adults, aged 15 to 59 years, who tested
HIV-positive during the five PHIA surveys, 10 031 (68%) had
initiated ART. Of those who had initiated ART, 121 (1.5%) had
stopped ART before the survey, and 9910 (98.5%) were still
receiving ART at the time of the survey. Out of those still on
ART at the time of the survey, we included 9200 (93.2%) par-
ticipants who were on ART for at least four months (Figure 1).
Most were women (64.2%) and resided in rural areas (59.5%).
The median age was 39 years (interquartile range [IQR], 32
to 46 years). Most (61.5%) were married or cohabitating. Few
(6.9%) reported being unaware of their HIV-positive status or
being HIV negative. Most (69.0%) had disclosed their HIV sta-
tus to a family member (Table 1, Table S1). The prevalence of
participants who screened positive for problematic or haz-
ardous drinking or active alcohol use disorder was 8.3%
(Table S2).
3.2 | Characteristics of and response to ART
Median duration on ART was reported as four years (IQR 2
to 7 years). Based on ARV testing, most participants (91.3%)
received an EFV-based first-line regimen and 90.6% reported
optimal adherence. The proportion of participants who
received second-line regimens ranged from 0.3% in Zimbabwe
to 3.4% in Eswatini. The median CD4 count was 467 cells/µL
(IQR 315 to 641 cells/µL). Overall, 20.5% (1837/8972) of par-
ticipants who received a plasma viral load test had a detect-
able VL of ≥40 copies/mL. The prevalence of VLS was 88.8%
(n = 8236), 11.2% (n = 964) had NVL including 8.2%
(n = 686) who had evidence of VF and 3.0% (n = 278) of
interrupted ART (Table 2). In the sensitivity analysis including
of participants who received ART for less than four months,
NVL prevalence was 12.4% (298/2416) in Lesotho, 8.8%
(131/1498) in Malawi, 9.0% in Swaziland (193/2175), 10.8%
(161/1542) in Zambia, 15.1% (314/2279) in Zimbabwe and
11.7% (1097/9910) across all five countries.
3.3 | Characteristics of participants with NVL
Table 3 shows the characteristics of participants with NVL.
One-quarter of participants with NVL (26.7%) had evidence of
interrupted ART, and three-quarters (73.3%) were experienc-
ing VF. Most participants with NVL (59.8%) were women.
Median age of participants with NVL was 36 years (IQR, 29
to 43 years). Median CD4 count among participants with VF
was 222 cells/µL (IQR 116 to 381 cells/µL), and median dura-
tion on ART was 4.5 years (IQR 2.6 to 6.9). Only 1.8% of par-
ticipants with VF received second-line ART.
3.4 | Factors associated with NVL
The adjusted odds ratios (aOR) for NVL for participants in
Zimbabwe (aOR 2.61; 95% confidence interval [CI]: 2.03 to
3.35), Lesotho (aOR 1.61; 95% CI: 1.26 to 2.05), and Zambia
(aOR 1.52; 95% CI: 1.14 to 2.02) were higher than in Eswa-
tini. The odds for NVL in people aged 15 to 24 years were 2
to 3 times higher than in those aged 45 to 59 years. The odds
of NVL were slightly increased in men (aOR 1.28; 95% CI:
1.05 to 1.55), in participants with low educational levels (aOR
1.27; 95% CI: 1.06 to 1.52), in those who had never married
(aOR 1.42; 95% CI: 1.02 to 1.98) and in those who had not
disclosed their HIV status to a family member (aOR 1.32;
95% CI: 1.06 to 1.66). Participants receiving NVP-based ART
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had higher odds for NVL (aOR 1.84; 95% CI: 1.34 to 2.51)
than those receiving EFV-based regimens. Odds for NVL were
also higher in participants who reported sub-optimal adher-
ence (aOR 1.81; 95% CI: 1.37 to 2.39; Table 4).
3.5 | Factors associated with VF and interrupted
ART among participants with NVL
Table 5 shows aORs comparing the odds for VF among par-
ticipants with NVL. The adjusted odds for VF among partici-
pants aged 15 to 19 years were lower (aOR 0.32; 95% CI:
0.14 to 0.76) than in those aged 44 to 59 years. Women had
almost half the odds (aOR 0.54; 95% CI: 0.29 to 0.99) of VF
compared to men. Married (aOR 0.53; 95% CI: 0.31 to 0.93)
and divorced participants (aOR 0.37; 95% CI: 0.19 to 0.71)
had lower odds for VF than participants who never married.
The odds for VF were 66% (aOR 0.34; 95% CI: 0.17 to 0.71)
and 68% (aOR 0.32; 95% CI: 0.17 to 0.59) lower in partici-
pants receiving ART for <1 year and one to two years, respec-
tively, compared to those receiving ART for five to ten years.
Participants with a CD4 count of 350 to 500 cells/µL (aOR
0.48 95% CI: 0.27 to 0.85) and those with a CD4 count
≥500 cells/µL (aOR 0.40 95% CI: 0.19 to 0.81) had lower
odds of VF than those with a CD4 cell count <100 cells/µL.
Factors associated with VF were inversely associated with
interrupted ART because participants with NVL either had VF
or interrupted ART.
3.6 | Rates of and factors associated with switching
to second-line ART
Overall, 131 (1.4%) of 8066 participants with known date of
ART initiation and known regimen switched to second-line
ART, for an annual switching rate of 0.31% (95% CI: 0.25 to
0.40). Annual switching rates were 0.22% (95% CI: 0.14 to
0.36) in Lesotho, 0.15% (95% CI: 0.08 to 0.35) in Malawi,
0.72% (95% CI: 0.54 to 0.96) in Eswatini, 0.73% (95% CI:
0.52 to 1.04) in Zambia and 0.06% (95% CI: 0.02 to 0.33) in
Zimbabwe. Compared to Eswatini, adjusted switching rates
were more than 10 times lower in Zimbabwe (IRR, 0.07; 95%
CI: 0.02 to 0.24), five times lower in Malawi (IRR 0.19; 95%
CI: 0.09 to 0.44), more than three times lower in Lesotho
(IRR 0.28; 95% CI: 0.15 to 0.52) and similar in Zambia (IRR
0.86; 95% CI: 0.57 to 1.32).
People with CD4 counts <100 cells/µL were more than
three times (IRR 3.52; 95% CI: 1.05 to 11.76) and those with
PLHIV in Eswa ni, Lesotho, Malawi, Zambia, and Zimbabwe aged 15-59 years 
13,852 (100.0%)*
Receiving ART at the 
me of the surveyb
9,910 (98.5%)†
Never used ARTb
3,667 (30.6%)*
Stopped ART before 
the surveyb
121 (1.5%)†
Missing data on HIV awareness 
or treatment statusa
154 (1.4%)*
Eligible par cipants
9,200 (93.2%)‡
Ini ated ARTb
10,031 (68.0%)*
Less than 4 months on ART 
710 (6.8%)‡
Figure 1. Flow diagram of inclusion of HIV-positive adults aged 15 to 59 years on antiretroviral therapy (ART) for at least four months who
participated in the Population-based HIV Impact Assessment (PHIA) survey in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to
2017). Data are unweighted numbers of participants and weighted percentages. Participants shown in red boxes were excluded. aWe excluded
participants with missing data on HIV awareness status, ART use, HIV RNA or ARV testing. bWe assessed ART use based on reported past and
current ART use to treat HIV infection and ARV testing results. Participants who reported no past or current ART use and who had no detectable
ARV blood levels were classified as having never used ART. Participants who reported past or current ART use or who had detectable ARV blood
levels were classified as having initiated ART. Participants who reported past but no current ART use and who had no detectable ARV blood levels
were classified as having ceased ART before the survey. Participants who reported receiving ART at the time of the survey, or who had detectable
ARV blood levels were classified as receiving ART at the time of the survey. *Denominators for percentages are PLHIV in Eswatini, Lesotho,
Malawi, Zambia and Zimbabwe aged 15 to 59 years. †Denominators for percentages are participants who initiated ART. ‡Denominators for per-
centages are participants who were on ART at the time of the survey. ART, antiretroviral therapy; ARV, antiretroviral drugs; PLHIV, people living
with HIV.
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CD4 counts of 100 to 199 cells/µL were more than two times
(IRR 2.29; 95% CI: 1.05 to 5.01) as likely to switch to second-
line ART than those with CD4 count of ≥500 cells/µL. Age,
sex and residence (rural or urban) were not associated with
switching rates.
Analysis of switching rates was not sensitive to assumptions
on the timing of switching. The overall annual switching rate
remained 0.31% whether we assumed that participants
switched six months after initiation of first-line ART or on the
day of the survey (Table S3).
4 | DISCUSSION
These population-based nationally representative surveys
showed that these five southern African countries are
approaching UNAIDS VLS targets despite limited access to VL
monitoring. We found that 88.8% of adults on ART achieved
VLS (VL < 1000 copies/mL), while 11.2% had NVL
(VL ≥ 1000 copies/mL). Sociodemographic characteristics, cur-
rent ART regimen, adherence and HIV status disclosure were
associated with NVL. One-quarter of participants with NVL
Table 1. Sociodemographic characteristics of HIV-positive adults receiving antiretroviral therapy in Lesotho, Malawi, Eswatini, Zam-
bia and Zimbabwe (2015 to 2017)
Characteristic
Lesotho Malawi Eswatini Zambia Zimbabwe Total
N = 2177 N = 1406 N = 2025 N = 1424 N = 2168 N = 9200
Residence, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
Urban 991 (49.8) 644 (24.9) 487 (29.1) 868 (62.3) 656 (35.8) 3646 (40.5)
Rural 1186 (50.2) 762 (75.1) 1538 (70.9) 556 (37.7) 1512 (64.2) 5554 (59.5)
Sex, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
Male 646 (38.0) 401 (35.6) 587 (30.3) 414 (35.8) 660 (36.3) 2708 (35.8)
Female 1531 (62.0) 1005 (64.4) 1438 (69.7) 1010 (64.2) 1508 (63.7) 6492 (64.2)
Age in years, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
15 to 19 56 (2.7) 22 (2.0) 70 (3.3) 29 (2.6) 83 (4.6) 260 (3.1)
20 to 24 116 (4.7) 76 (4.3) 124 (6.1) 65 (4.9) 85 (4.4) 466 (4.6)
25 to 44 1293 (61.6) 923 (65.0) 1294 (67.0) 895 (62.2) 1287 (61.4) 5692 (62.9)
45 to 59 712 (30.9) 385 (28.7) 537 (23.6) 435 (30.3) 713 (29.7) 2782 (29.3)
Median (IQR) 39 (32 to 47) 39 (32 to 45) 37 (30 to 44) 40 (33 to 46) 39 (32 to 46) 39 (32 to 46)
Wealth quintile, n (%) 2174 (100.0) 1406 (100.0) 2024 (100.0) 1413 (100.0) 2168 (100.0) 9185 (100.0)
Lowest 440 (17.4) 147 (14.1) 512 (23.1) 119 (8.2) 554 (21.1) 1772 (15.8)
Second 493 (21.3) 172 (17.0) 457 (21.7) 157 (10.8) 436 (18.6) 1715 (16.7)
Middle 480 (22.5) 193 (18.3) 429 (20.7) 295 (20.2) 399 (19.2) 1796 (19.6)
Fourth 400 (20.0) 287 (23.4) 349 (19.2) 371 (26.0) 393 (21.7) 1800 (22.9)
Highest 361 (18.8) 607 (27.1) 277 (15.3) 471 (34.8) 386 (19.3) 2102 (24.9)
Education, n (%) 2176 (100.0) 1405 (100.0) 2022 (100.0) 1424 (100.0) 2168 (100.0) 9195 (100.0)
No or primary 1309 (59.1) 999 (77.5) 890 (41.3) 649 (44.0) 891 (36.9) 4738 (51.7)
Secondary or higher 867 (40.9) 406 (22.5) 1132 (58.7) 775 (56.0) 1277 (63.1) 4457 (48.3)
Marital status, n (%) 2171 (100.0) 1404 (100.0) 2012 (100.0) 1420 (100.0) 2163 (100.0) 9170 (100.0)
Never married 330 (15.5) 76 (4.6) 654 (33.0) 133 (10.2) 208 (10.0) 1401 (10.6)
Married/living together 1130 (54.4) 909 (65.9) 1019 (50.5) 873 (63.1) 1287 (61.0) 5218 (61.5)
Divorced, separated or
widowed
711 (30.1) 419 (29.5) 339 (16.5) 414 (26.7) 668 (29.0) 2551 (27.9)
Economic support, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
No 1720 (80.4) 1302 (91.1) 1204 (60.7) 1364 (95.8) 1871 (87.1) 7461 (88.1)
Yes 457 (19.6) 104 (8.9) 821 (39.3) 60 (4.2) 297 (12.9) 1739 (11.9)
Paid work, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1421 (100.0) 2167 (100.0) 9196 (100.0)
Yes 871 (43.9) 480 (32.8) 936 (48.5) 537 (40.2) 763 (37.4) 3587 (38.2)
No 1306 (56.1) 926 (67.2) 1089 (51.5) 884 (59.8) 1404 (62.6) 5609 (61.8)
Disclosure to a family member,
n (%)
2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
No 540 (25.9) 344 (24.2) 660 (32.6) 291 (20.5) 507 (24.9) 2342 (24.2)
Yes 1525 (68.1) 977 (69.4) 1307 (64.1) 1005 (70.1) 1544 (68.8) 6358 (69.0)
Unknown (unaware of HIV
status)
112 (5.9) 85 (6.4) 58 (3.3) 128 (9.3) 117 (6.3) 500 (6.9)
IQR, interquartile range; N, Number of eligible participants; n, number of participants providing a valid response (weighted %).
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had no detectable blood concentrations of ARVs and were
classified as having interrupted ART, while three-quarters of
participants with NVL had evidence of recent ARV exposure
and were classified as experiencing VF. Marriage, female sex,
shorter ART duration, higher CD4 count and alcohol use were
associated with higher odds for interrupted ART and lower
odds for VF. Almost half of the people with VF were severely
immunosuppressed although they received ART for several
years. Switching rates varied considerably between countries,
but even in countries with the highest switching rates, very
few patients had switched to second-line therapy.
Low switching rates, as documented in this study, indicate
substantial gaps in monitoring of ART and/or clinical manage-
ment of patients with treatment failure. HIV cohort studies
Table 2. Characteristics of and response to antiretroviral therapy (ART) among HIV-positive adults in Lesotho, Malawi, Eswatini,
Zambia and Zimbabwe (2015 to 2017)
Lesotho Malawi Eswatini Zambia Zimbabwe Total
N = 2177 N = 1406 N = 2025 N = 1424 N = 2168 N = 9200
Duration on ART, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
4 to 12 months 336 (15.6) 144 (10.2) 251 (12.8) 169 (12.1) 216 (10.7) 1116 (11.5)
1 to 2 years 285 (13.3) 188 (13.3) 283 (13.8) 186 (13.5) 275 (12.4) 1217 (13.1)
2 to 5 years 574 (25.9) 434 (30.8) 613 (30.0) 383 (26.3) 734 (33.6) 2738 (30.1)
5 to 10 years 630 (28.3) 417 (29.4) 609 (29.9) 415 (28.1) 702 (31.2) 2773 (29.6)
>10 years 153 (7.0) 104 (7.1) 162 (7.5) 108 (7.9) 81 (3.8) 608 (6.2)
Missing 199 (9.9) 119 (9.3) 107 (5.9) 163 (12.0) 160 (8.3) 748 (9.5)
Median (IQR) 4 (1 to 7) 4 (2 to 7) 4 (2 to 7) 4 (2 to 7) 4 (2 to 6) 4 (2 to 7)
ART regimen, n (%) 2076 (100.0) 1357 (100.0) 1956 (100.0) 1365 (100.0) 2049 (100.0) 8803 (100.0)
EFV-based 1750 (84.7) 1257 (93.1) 1477 (76.2) 1223 (89.3) 1970 (96.3) 7677 (91.3)
NVP-based 303 (14.1) 87 (6.2) 412 (20.4) 98 (7.4) 74 (3.4) 974 (7.2)
LPV-based 23 (1.2) 0 (0.0) 67 (3.4) 42 (3.1) 5 (0.3) 137 (1.2)
ATV-based NA 13 (0.7) NA 2 (0.1) NA 15 (0.2)
Adherence, n (%) 2022 (100.0) 1299 (100.0) 1881 (100.0) 1266 (100.0) 2019 (100.0) 8487 (100.0)
Optimal 1769 (87.1) 1142 (87.4) 1692 (90.1) 1154 (90.7) 1908 (94.2) 7665 (90.6)
Suboptimal 253 (12.9) 157 (12.6) 189 (9.9) 112 (9.3) 111 (5.8) 822 (9.4)
CD4 count per µL, n (%) 2177 (100.0) 1405 (100.0) 2024 (100.0) 1420 (100.0) 2166 (100.0) 9192 (100.0)
<100 52 (2.6) 34 (2.4) 25 (1.3) 35 (2.6) 74 (3.9) 220 (2.9)
100 to 199 120 (6.1) 91 (7.5) 68 (3.5) 105 (7.9) 177 (9.4) 561 (7.8)
200 to 349 321 (15.4) 236 (16.4) 249 (12.5) 273 (19.5) 503 (23.7) 1582 (19.3)
350 to 499 462 (21.9) 342 (24.5) 436 (21.5) 405 (28.1) 573 (25.2) 2218 (25.2)
≥500 1222 (54.0) 702 (49.2) 1246 (61.2) 602 (41.9) 839 (37.8) 4611 (44.8)
Median (IQR) 528 (360 to
701)
497 (338 to 652) 571 (409 to
769)
457 (311 to 622) 422 (278 to
591)
467 (315 to 641)
Viral load in copies/mL, n
(%)a
2099 (100.0) 1399 (100.0) 1973 (100.0) 1343 (100.0) 2158 (100.0) 8972 (100.0)
<40 1627 (77.2) 1212 (85.7) 1577 (79.3) 1055 (78.6) 1664 (75.8) 7135 (79.5)
40 to 999 238 (11.6) 69 (5.6) 232 (12.3) 153 (11.1) 206 (9.6) 898 (9.2)
≥1000 234 (11.2) 118 (8.7) 164 (8.4) 135 (10.3) 288 (14.6) 939 (11.3)
ART outcome, n (%) 2177 (100.0) 1406 (100.0) 2025 (100.0) 1424 (100.0) 2168 (100.0) 9200 (100.0)
Viral load suppression 1929 (88.5) 1287 (91.3) 1858 (91.7) 1285 (90.1) 1877 (85.3) 8236 (88.8)
Nonsuppressed viral
load
248 (11.5) 119 (8.7) 167 (8.3) 139 (9.9) 291 (14.7) 964 (11.2)
Virologic failure 174 (8.0) 75 (5.8) 116 (5.7) 99 (7.2) 222 (11.5) 686 (8.2)
Interrupted ART 74 (3.5) 44 (2.9) 51 (2.6) 40 (2.8) 69 (3.2) 278 (3.0)
Vial load suppression: viral load < 1000 copies/mL; nonsuppressed viral load: viral load ≥ 1000 copies/mL. Virologic failure: nonsuppressed viral
load and antiretroviral drugs detected; interrupted ART: nonsuppressed viral load and no antiretroviral drugs detected. Adherence was defined as
optimal if a participant reported missing less than two doses of ART in the last 30 days and suboptimal if a participant reported missing two or
more doses in the last 30 days. N, number of eligible participants; n, number of participants providing a valid response (weighted %). IQR,
interquartile range; ART, antiretroviral therapy; EFV, efavirenz; NVP, nevirapine; LPV, lopinavir; ATV, atazanavir.
a
Dried blood spot viral load test results (n = 228) could not be classified and were excluded.
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Table 3. Characteristics of adults on antiretroviral therapy with nonsuppressed viral load: Results from the Lesotho, Malawi, Eswa-
tini, Zambia and Zimbabwe Population-based HIV Impact Assessment survey (2015 to 2017)
Interrupted ART Virologic failure Nonsuppressed viral load
N = 278 [26.7%] N = 686 [73.3%] N = 964 [100.0%]
Sex, n (%) 278 (100.0) 686 (100.0) 964 (100.0)
Male 68 (28.9) 246 (44.3) 314 (40.2)
Female 210 (71.1) 440 (55.7) 650 (59.8)
Age in years, n (%) 278 (100.0) 686 (100.0) 964 (100.0)
15 to 19 19 (6.8) 45 (5.7) 64 (6.0)
20 to 24 36 (10.8) 58 (7.4) 94 (8.3)
25 to 44 184 (66.4) 439 (66.5) 623 (66.5)
45 to 59 39 (15.9) 144 (20.4) 183 (19.2)
Median (IQR) 34 (27 to 41) 37 (30 to 43) 36 (29 to 43)
Marital status, n (%) 277 (100.0) 681 (100.0) 958 (100.0)
Never married 60 (13.1) 148 (17.5) 208 (16.4)
Married or living together 149 (56.6) 360 (60.5) 509 (59.5)
Divorced, separated or widowed 68 (30.2) 173 (21.9) 241 (24.2)
AUDIT-C score, n (%) 202 (100.0) 506 (100.0) 708 (100.0)
0 171 (82.4) 417 (81.5) 588 (81.7)
1 to 2 13 (6.9) 43 (9.3) 56 (8.7)
3 to 4 5 (3.7) 26 (4.9) 31 (4.6)
5 to 8 9 (4.0) 18 (4.0) 27 (4.0)
9 to 12 4 (3.0) 2 (0.3) 6 (1.0)
Antiretroviral drug detected, n (%) 278 (100.0) 686 (100.0) 964 (100.0)
EFV 0 (0.0) 567 (87.6) 567 (64.2)
NVP 0 (0.0) 105 (10.7) 105 (7.8)
LPV 0 (0.0) 12 (1.4) 12 (1.0)
ATV 0 (0.0) 2 (0.4) 2 (0.3)
No ARVs detected 278 (100.0) 0 (0.0) 278 (26.7)
Duration on ART, n (%) 271 (100.0) 564 (100.0) 835 (100.0)
4 to 12 months 58 (18.7) 53 (10.1) 111 (12.7)
1 to 2 years 53 (19.9) 65 (10.1) 118 (13.1)
2 to 5 years 83 (30.4) 191 (34.8) 274 (33.5)
5 to 10 years 59 (23.1) 204 (36.4) 263 (32.4)
>10 years 18 (8.0) 51 (8.6) 69 (8.4)
Median (IQR) 2.9 (1.2 to 5.8) 4.5 (2.6 to 6.9) 4.2 (1.9 to 6.6)
CD4 cell count per µL, n (%) 276 (100.0) 685 (100.0) 961 (100.0)
<100 33 (12.7) 128 (21.7) 161 (19.3)
100 to 199 52 (21.2) 139 (23.1) 191 (22.6)
200 to 349 68 (22.0) 170 (25.7) 238 (24.7)
350 to 499 61 (21.8) 129 (16.4) 190 (17.8)
≥500 62 (22.4) 119 (13.2) 181 (15.6)
Median (IQR) 300 (165 to 497) 222 (116 to 381) 237 (126 to 414)
Viral load log10 copies/mL, n (%)
3 to 4 59 (20.2) 254 (35.9) 313 (31.7)
4 to 5 152 (56.0) 299 (44.0) 451 (47.2)
5 to 6 61 (22.0) 125 (19.1) 186 (19.9)
≥6 6 (1.9) 8 (1.0) 14 (1.2)
Median (IQR) 4.5 (4.2 to 5.0) 4.3 (3.8 to 4.8) 4.4 (3.8 to 4.9)
Nonsuppressed viral load was defined as viral load ≥1000 copies/mL. ART, antiretroviral therapy; EFV, efavirenz; IQR, interquartile range; LPV,
lopinavir: ATV, atazanavir; N, number of eligible participants; n, number of participants providing a valid response (weighted col %) [weighted row
%]; NVP, nevirapine.
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from low-income and middle-income countries showed that
each year about 3% of adults have a confirmed virologic treat-
ment failure of first-line ART and require switching to second-
line ART [6,35]. We found nationally representative switching
rates far below the annual failure rate of 3%: annual switching
rates in our study ranged from 0.06% to 0.73%. Limited
access to VL monitoring likely explains these low switching
rates. When PHIA data were collected, the five countries
mainly relied on CD4 monitoring and clinical monitoring with
limited access to targeted VL testing [10,36,37]. Without
routine VL monitoring, treatment failure often remains unde-
tected and patients are not switched to second-line ART, or
patients are switched late and at low CD4 cell counts [6]. Our
study demonstrates the limitations of clinical and immunologi-
cal monitoring of ART and supports country-level efforts to
scale-up VL testing for early detection of NVL.
Once patients with NVL have been identified, healthcare
providers need to distinguish between patients who require
adherence support and those who need a new ART regimen.
We noted that more than one-quarter of participants with
Table 4. Factors associated with nonsuppressed viral load among HIV-positive participants in the Population-based HIV Impact
Assessment survey in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017)
Nonsuppressed viral load
Bivariate analysis
Multivariable analysis
OR (95% CI) P-value aOR (95% CI) P-value
Characteristics of participants
Country of residence <0.001 <0.001
Lesotho 1.43 (1.14 to 1.79) 1.61 (1.26 to 2.05)
Malawi 1.05 (0.78 to 1.44) 1.25 (0.90 to 1.74)
Eswatini 1.00 1.00
Zambia 1.22 (0.94 to 1.57) 1.52 (1.14 to 2.02)
Zimbabwe 1.90 (1.53 to 2.35) 2.61 (2.03 to 3.35)
Age, years <0.001 <0.001
15 to 19 3.47 (2.23 to 5.41) 2.15 (1.23 to 3.78)
20 to 24 3.17 (2.17 to 4.62) 3.13 (2.08 to 4.71)
25 to 44 1.70 (1.34 to 2.14) 1.81 (1.42 to 2.32)
45 to 59 1.00 1.00
Sex 0.022 0.013
Male 1.24 (1.03 to 1.48) 1.28 (1.05 to 1.55)
Female 1.00 1.00
Marital status <0.001 0.110
Never married 1.72 (1.33 to 2.23) 1.42 (1.02 to 1.98)
Married or living together 1.00 1.00
Divorced, separated or widowed 0.89 (0.72 to 1.09) 1.02 (0.82 to 1.27)
Education 0.977 0.010
No or primary 1.00 (0.83 to 1.20) 1.27 (1.06 to 1.52)
Secondary or higher 1.00 1.00
Disclosure to a family member 0.003 0.014
No 1.29 (1.04 to 1.61) 1.32 (1.06 to 1.66)
Yes 1.00 1.00
Not self-reported positive 1.64 (1.16 to 2.32) 1.39 (0.96 to 2.02)
Characteristics of antiretroviral therapy
Antiretroviral regimen 0.003 0.001
EFV-based 1.00 1.00
NVP-based 1.66 (1.23 to 2.24) 1.84 (1.34 to 2.51)
PI-based 1.65 (0.80 to 3.39) 1.86 (0.88 to 3.89)
Adherence <0.001 <0.001
Optimal 1.00 1.00
Suboptimal 1.91 (1.46 to 2.50) 1.81 (1.37 to 2.39)
Multivariable analysis adjusted for country, age, sex, marital status, education, disclosure of HIV status to a family member, antiretroviral regimen
and adherence. Nonsuppressed viral load was defined as viral load ≥1000 copies/mL. P-values of categorical variables are for joint test for signifi-
cance. aOR, adjusted odds ratios; ART, antiretroviral therapy; EFV, efavirenz; NVP, nevirapine; OR, odds ratio; PI, protease inhibitor.
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NVL tested negative for recent exposure to ARVs, indicating
that temporary interruption of ART was the likely reason for
NVL in these individuals. Young women, those with high CD4
cell counts, and those who were on ART for <2 years were
more likely to interrupt ART. Suboptimal retention and adher-
ence among women who started ART during pregnancy under
Option B+ guidelines which recommend rapid ART initiation
for pregnant and breastfeeding women may explain these
findings [38-40]. In line with previous data, our study suggests
that a substantial proportion of people with NVL interrupted
ART and may benefit from adherence interventions. The ANRS
12110 trial showed that one-third of patients with NVL had
no viral resistance [41]. The DART trial showed that one-third
of patients with NVL re-suppressed without changing their
ART regimen [42]. A systematic review of five observational
studies from South Africa, Eswatini, Thailand and France
showed that more than 70% of patients with NVL re-sup-
pressed following adherence intervention [43]. In agreement
with earlier reports, our study supports WHO guidelines to
offer adherence support and confirmatory VL testing to
patients with a first NVL to avoid unnecessary switching of
ART [9]. Our study also underlines the importance of
Table 5. Factors associated with virologic failure among participants with nonsuppressed viral load in Eswatini, Lesotho, Malawi,
Zambia and Zimbabwe (2015 to 2017)
Virologic failure
Bivariate analysis Multivariable analysis
OR (95% CI) P-value aOR (95% CI) P-value
Sociodemographic characteristics
Age in years 0.250 0.056
15 to 19 0.66 (0.30 to 1.47) 0.32 (0.14 to 0.76)
20 to 24 0.53 (0.28 to 1.01) 0.54 (0.24 to 1.18)
25 to 44 0.78 (0.49 to 1.23) 0.89 (0.56 to 1.42)
45 to 59 1.00 1.00
Sex 0.002 0.047
Male 1.00 1.00
Female 0.51 (0.34 to 0.78) 0.54 (0.29 to 0.99)
Marital status 0.043 0.012
Never married 1.00 1.00
Married or living together 0.80 (0.53 to 1.20) 0.53 (0.31 to 0.93)
Divorced, separated or widowed 0.54 (0.34 to 0.88) 0.37 (0.19 to 0.7)
Antiretroviral therapy characteristics
Duration on ART in years 0.001 <0.001
<1 0.39 (0.20 to 0.76) 0.34 (0.17 to 0.71)
1 to 2 0.37 (0.21 to 0.65) 0.32 (0.17 to 0.59)
2 to 5 0.74 (0.47 to 1.17) 0.75 (0.45 to 1.24)
5 to 10 1.00 1.00
>10 0.69 (0.33 to 1.40) 0.62 (0.30 to 1.26)
CD4 cell count per µL 0.004 0.048
<100 1.00 1.00
100 to 199 0.65 (0.40 to 1.05) 0.59 (0.37 to 0.95)
200 to 349 0.69 (0.38 to 1.25) 0.67 (0.37 to 1.21)
350 to 499 0.44 (0.26 to 0.76) 0.48 (0.27 to 0.85)
≥500 0.35 (0.19 to 0.63) 0.40 (0.19 to 0.81)
Behavioural characteristics
AUDIT-C score <0.001 0.001
0 1.00 1.00
1 to 2 1.33 (0.67 to 2.63) 1.01 (0.41 to 2.47)
3 to 4 1.26 (0.76 to 2.11) 0.93 (0.46 to 1.87)
5 to 8 1.00 (0.55 to 1.81) 0.55 (0.26 to 1.20)
9 to 12 0.10 (0.04 to 0.28) 0.09 (0.03 to 0.28)
Nonsuppressed viral load was defined as a viral load of ≥1000 copies/mL. Multivariable analysis adjusted for all variables shown in the table. P-val-
ues of categorical variables are for joint test for significance. aOR, adjusted odds ratios; ART, antiretroviral therapy; ARV, antiretroviral medication;
OR, odds ratio.
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adherence support for patients who start ART with high CD4
cell counts, especially during the initial phase of treatment.
Optimizing ART regimens likely can support countries’
efforts to increase VLS rates among people receiving ART. In
December 2018, WHO recommended dolutegravir (DTG),
tenofovir (TDF), and either lamivudine or emtricitabine (XTC)
as the preferred first-line regimen, and low- and middle-in-
come countries are transitioning from the current first-line
regimen TDF/XTC/EFV to the new DTG-based regimen [44].
DTG is safer and has a higher genetic barrier to resistance
than EFV. Data from randomized controlled trials support
switching people with undetectable VL from an EFV-based
regimen to a DTG-based regimen; however, currently, no evi-
dence supports this switch for those with detectable or
unknown VL [45]. Our finding that about 20% of people
receiving ART had a detectable VL > 40 copies/mL underlines
the need for data to support switching from a failing current
first-line treatment to effective second-line treatments. How-
ever, the effectiveness of switching from TDF/XTC/EFV to
TDF/XTC/DTG needs to be evaluated. Our data suggest that
men, individuals who never married, and those with a poor
immunologic response to long-term ART are at increased risk
of VF and should be monitored carefully after switching to
DTG.
Our study has several strengths and limitations. The
national representativeness of our findings and the richness
of collected sociodemographic, behavioural and laboratory
data including measures on viral suppression and ARV detec-
tion are important strengths of our study. Our findings have
to be considered in the view of several limitations. Our defi-
nition of VF did not rely on drug resistance data, and our
ability to distinguish between patients with NVL due to inad-
equate adherence, drug resistance or both was limited. We
classified participants as having interrupted or failing ART
based on self-report of current ART use and laboratory test-
ing for detectable concentrations of selected ARVs. Both
data sources have limitations that may lead to misclassifica-
tion. Self-reported data on ART might be susceptible to
recall and social desirability bias. Likewise, laboratory errors
could result in misclassification. We also acknowledge that
our estimates for the prevalence of participants who inter-
rupted ART do not include individuals who stopped ART
before the survey. In our study, only 1.5% of the participants
with a history of ART use reported having stopped ART
before the survey. HIV cohort studies found higher rates of
treatment discontinuation [8,46-48]. PHIA estimates for
treatment discontinuation might be an underestimate
because PLHIV who stopped ART might underreport prior
ART use or awareness of their own HIV status. The PHIA
survey only included people who were alive. High mortality
among individuals who remain on failing first-line regimens
might partially explain the low NVL prevalence among those
who survived and were included in the survey [6,49]. Finally,
the rates of switching to second-line ART in Lesotho, Eswa-
tini and Zimbabwe may be underestimates because samples
from these countries were tested for LPV but not ATV,
although both drugs are WHO-recommended second-line
treatments [9]. However, the ARVs tested were selected
according to national treatment guidelines, and we assumed
very few people in Lesotho, Eswatini and Zimbabwe would
have received ATV.
5 | CONCLUSIONS
The five countries included in our analysis have low rates of
NVL and are approaching UNAIDS VLS targets, despite lim-
ited access to VL monitoring and possible suboptimal clinical
management of patients with NVL. Treatment support, in par-
ticular for younger adults, and people with higher CD4 counts,
and switching of patients to PI- or DTG-based regimens may
further reduce NVL prevalence.
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